BWAY
BrainsWay Ltd.
BWAY has a slight edge over OSCR overall, supported by lower modeled downside and stronger fundamentals.
OSCR
Oscar Health, Inc.
OSCR offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
BWAY Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Stable | |
| Healthy |
BWAY's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
BWAY PE Valuation
BWAY has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
BWAY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for BWAY, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
BWAY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $0.37 | +147% |
| Q1 2026 | $0.28 | +133% |
| Q4 2025 | $0.18 | +80% |
| Q3 2025 | $0.15 | +114% |
| Q2 2025 | $0.15 | +650% |
| Q1 2025 | $0.12 | +$0.17 |
| Q4 2024 | $0.10 | +$0.22 |
| Q3 2024 | $0.07 | +$0.32 |
BWAY has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
BWAY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $17.4M | +38% |
| Q1 2026 | $15.5M | +35% |
| Q4 2025 | $14.5M | +27% |
| Q3 2025 | $13.5M | +29% |
| Q2 2025 | $12.6M | +26% |
| Q1 2025 | $11.5M | +27% |
| Q4 2024 | $11.4M | +26% |
| Q3 2024 | $10.5M | +26% |
BWAY's revenue has grown year over year for 12 quarters in a row: $17M last quarter, up 38% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 14% | +9.4 points |
| Q1 2026 | 13% | +7.9 points |
| Q4 2025 | 13% | +9.4 points |
| Q3 2025 | 9.3% | +6.6 points |
| Q2 2025 | 4.6% | -1.3 points |
| Q1 2025 | 5% | +4 points |
| Q4 2024 | 3.8% | -108 points |
| Q3 2024 | 2.7% | +4.3 points |
BWAY has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over BWAY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
BWAY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $5.5M | -51% |
| Q1 2026 | $402K | -90% |
| Q4 2025 | -$759K | -130% |
| Q3 2025 | $586K | -40% |
| Q2 2025 | $11.2M | +2139% |
| Q1 2025 | $4M | +62% |
| Q4 2024 | $2.6M | +27% |
| Q3 2024 | $978K | +16% |
BWAY still generates free cash flow, though less than at its 2025 peak: $6M over the past year.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over BWAY on cash flow, with more consistent year-over-year improvement.
BWAY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.1% | +981K shares |
| 1 year | -47% | -17.7M shares |
| 3 years | -40% | -13.1M shares |
| 5 years | -39% | -12.8M shares |
| Available history | -8.5% | -1.9M shares |
BWAY has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
BWAY hasn't bought back shares in the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
BWAY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -4.5x | Net Cash |
| Q1 2026 | -4.1x | Net Cash |
| Q4 2025 | -5.2x | Net Cash |
| Q3 2025 | -6.6x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -10.0x | Net Cash |
| Q4 2024 | -11.9x | Net Cash |
| Q3 2024 | -8.6x | Net Cash |
BWAY has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
BWAY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.9 | Oversold |
| Stochastic | 5.3 | Oversold |
BWAY's weekly RSI is 30 (oversold) and its Stochastic is 5 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
BWAY PE vs Healthcare Sector
| Metric | BWAY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
BWAY has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
BWAY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.6 | 12% below |
| 20 week MA | $13.6 | 25% below |
| 50 week MA | $13.2 | 22% below |
| 100 week MA | $9.61 | 6.7% above |
| 200 week MA | $6.08 | 69% above |
BWAY has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 69% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over BWAY on trend strength, trading above more of its moving averages.
BWAY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $4.85 | $3.09 | -36% |
| 2021 | $3.09 | $3.76 | +22% |
| 2022 | $3.76 | $1.08 | -71% |
| 2023 | $1.08 | $3.24 | +200% |
| 2024 | $3.24 | $4.57 | +41% |
| 2025 | $4.57 | $9.69 | +112% |
| 2026 YTD | $9.69 | $10.3 | +5.8% |
BWAY's yearly returns have swung widely, from +200% in 2023 to −71% in 2022. It's up 5.8% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over BWAY on returns for 2026, with the stronger performance.